Attana has received a 5-year service and support contract from a leading health institute in the US

The order is a result of the strategic business plan that Attana launched prior to the Covid-19 pandemic, which has been on hold during the pandemic.

The order is for a 5-year “Gold” service and support agreement and includes both technical support and maintenance as well as application and assay support. The order is a result of a strategic business plan that was initiated before the pandemic, which has, however, since been on hold. The first step of the plan is to revitalize a number of select strong, reputable and successful Attana customers as reference sites which are important for consecutive steps in order to establish and maintain growing market share in the US long-term. This is the second US customer order targeted 2022 according to plan. The customer is a leading health institution in the US and the initial task for Attana is to perform annual service and maintenance schedule followed by user training. The order will affect Attana's cash flow and earnings continuously in the coming 5 years.

Attana´s Sales Manager Thomas Ljungberg comments:

“This order confirms Attana’s unique offering to provide crucial information. It is enabled by our clients’ successful track records in clinical trials as well as our ability to meet this particular client´s needs. The order demonstrates the demand for our technology and capability to characterize interactions with cells and tissues as well as in blood, sera and plasma.”

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: